You’ll discover the most effective ways to prevent and beat cancer — from 131 of the world’s top experts — that you won’t hear about elsewhere.

Click Here for Exclusive Access!
n/a
Abstract Title:

Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis.

Abstract Source:

Eur Neuropsychopharmacol. 2016 Nov ;26(11):1752-1759. Epub 2016 Sep 19. PMID: 27659240

Abstract Author(s):

Ymkje Anna de Vries, Annelieke M Roest, Lian Beijers, Erick H Turner, Peter de Jonge

Article Affiliation:

Ymkje Anna de Vries

Abstract:

Previous research has shown that reporting bias has inflated the apparent efficacy of antidepressants. We investigated whether apparent safety was also affected. We included 133 trials, involving 31,296 patients, of second-generation antidepressants for the treatment of major depressive disorder (MDD) or anxiety disorders, obtained from Food and Drug Administration (FDA) reviews. We extracted data on overall discontinuation, discontinuation due to adverse events, and serious adverse events (SAEs). Meta-analysis was used to compare discontinuation rates between FDA reviews and matching journal articles, while SAEs were compared qualitatively. The odds ratio for overall discontinuation, comparing drug to placebo, was 1.0 for both sources, while that for discontinuation due to adverse events was 2.4 for both sources. Seventy-seven of 97 (79%) journal articles provided incomplete information on SAEs; sixty-one (63%) articles made no mention of SAEs at all. Of 21 articles which could be compared to the FDA, only 6 (29%) had full reporting without discrepancies. Nine (43%) articles reported a discrepant number of SAEs. Descriptions were absent or discrepant in 6 (29%) additional articles, even for important SAEs such as suicide attempts. In conclusion, reporting bias has not affected average discontinuation rates over trials. However, SAE reporting is not only very poor, with over half of articles failing to discuss SAEs altogether, but discrepancies between the FDA and articles were common and often led to a more favorable drug-placebo comparison. These findings suggest that journal articles are an unreliable source of data on SAEs in antidepressant trials.

Study Type : Meta Analysis
Additional Links

Print Options


Key Research Topics

You’ll discover the most effective ways to prevent and beat cancer — from 131 of the world’s top experts — that you won’t hear about elsewhere.

Click Here for Exclusive Access!

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2017 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.